tetano
Editor, Senior Moderator
Infect Disord Drug Targets
. 2022 Jan 7.
doi: 10.2174/1871526522666220107141109. Online ahead of print.
Procalcitonin as a prognostic factor in patients with COVID-19 in southwestern Iran
Milad Shahini Shams Abadi[SUP] 1 [/SUP], Elham Taheri[SUP] 2 [/SUP], Ahmad Raesi[SUP] 3 [/SUP], Mohammad-Hassan Arjmand[SUP] 1 [/SUP], Soleiman Kheirii[SUP] 4 [/SUP], Najmeh Shahinfard[SUP] 5 [/SUP], Zahra Habibi[SUP] 5 [/SUP]
Affiliations
Abstract
Background: There is increasing evidence supporting a central role of the viral-induced hyper-inflammatory immune response in the pathogenesis of COVID-19. Serum procalcitonin (PCT) is an emerging prognostic marker in coronavirus disease 2019 (COVID-19). The aim of this study was to investigate the relationship between serum procalcitonin and clinical severity and outcomes in patients with coronavirus disease 2019 (COVID-19).
Materials and methods: Hematological and biochemical parameters were evaluated in patients with COVID-19 infection from February to April 2020 at Hajar Hospital in the Shahrekord University of Medical Science, Shahrekord, Iran.
Results: The results showed that total lymphocyte counts, albumin, calcium, and creatinine levels were significant different between the two moderate and severe groups, and the mean of procalcitonin level in COVID-19 patients with severe disease was higher (0.36 ng/mL) compared with the patients with moderate disease, and its level was found to be >5 ng/mL in 14.2% of5 ng/mL in 14.2% of patients in the former group.
Conclusions: PCT may be a marker of disease severity in COVID-19 and may contribute to determine the severity of patients infected with SARS-CoV-2. Moreover, serial PCT measurements may be beneficial in predicting the prognosis.
Keywords: Albumin; Calcium; Covid-19; Creatinine; Procalcitonin; Prognosis.
. 2022 Jan 7.
doi: 10.2174/1871526522666220107141109. Online ahead of print.
Procalcitonin as a prognostic factor in patients with COVID-19 in southwestern Iran
Milad Shahini Shams Abadi[SUP] 1 [/SUP], Elham Taheri[SUP] 2 [/SUP], Ahmad Raesi[SUP] 3 [/SUP], Mohammad-Hassan Arjmand[SUP] 1 [/SUP], Soleiman Kheirii[SUP] 4 [/SUP], Najmeh Shahinfard[SUP] 5 [/SUP], Zahra Habibi[SUP] 5 [/SUP]
Affiliations
- PMID: 34994319
- DOI: 10.2174/1871526522666220107141109
Abstract
Background: There is increasing evidence supporting a central role of the viral-induced hyper-inflammatory immune response in the pathogenesis of COVID-19. Serum procalcitonin (PCT) is an emerging prognostic marker in coronavirus disease 2019 (COVID-19). The aim of this study was to investigate the relationship between serum procalcitonin and clinical severity and outcomes in patients with coronavirus disease 2019 (COVID-19).
Materials and methods: Hematological and biochemical parameters were evaluated in patients with COVID-19 infection from February to April 2020 at Hajar Hospital in the Shahrekord University of Medical Science, Shahrekord, Iran.
Results: The results showed that total lymphocyte counts, albumin, calcium, and creatinine levels were significant different between the two moderate and severe groups, and the mean of procalcitonin level in COVID-19 patients with severe disease was higher (0.36 ng/mL) compared with the patients with moderate disease, and its level was found to be >5 ng/mL in 14.2% of5 ng/mL in 14.2% of patients in the former group.
Conclusions: PCT may be a marker of disease severity in COVID-19 and may contribute to determine the severity of patients infected with SARS-CoV-2. Moreover, serial PCT measurements may be beneficial in predicting the prognosis.
Keywords: Albumin; Calcium; Covid-19; Creatinine; Procalcitonin; Prognosis.